<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519635</url>
  </required_header>
  <id_info>
    <org_study_id>2011DR3137</org_study_id>
    <nct_id>NCT01519635</nct_id>
  </id_info>
  <brief_title>Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension</brief_title>
  <official_title>Effect of Aliskiren 300mg and Hydrochlorothiazide 25mg on Kidney Oxygenation in Patients With Stage 1 and 2 Hypertension: a BOLD-MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to evaluate the chronic effect (8 weeks) of RASILEZ 300mg
      (aliskiren) on renal tissue oxygenation in patients with stage 1-2 hypertension, and to
      compare the chronic effect (8 weeks) of RASILEZ 300mg (aliskiren) on renal tissue oxygenation
      in patients with stage 1-2 hypertension with these effects with those of ESIDREX 25mg
      (hydrochlorothiazide).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      36 patients with arterial hypertension stage 1-2 (blood pressure: 140/90 and 180/110 mm Hg)
      will be included in this study and randomized to two groups of 18 patients each: one group
      will receive RASILEZ 300mg (aliskiren) and one group ESIDREX 25mg (hydrochlorothiazide).

      After a two week washout of antihypertensive drugs, baseline and the chronic effect (8 week
      study drug) of each group will be studied with precise renal hemodynamic measurements (inulin
      clearance, PAH renal plasma and blood flow, sodium and endogenous lithium excretion, plasma
      renin, plasma aldosterone, urinary sodium and potassium) and assessment of renal oxygenation
      with BOLD-MRI (blood oxygen level detection - magnetic resonance imaging).

      Drug therapy will be started with an initial 2 weeks on Rasilez 150 mg or HCTZ 12.5 mg
      followed by a titration to 300 mg Rasilez and 25 mg HCTZ if the treatment is well tolerated.
      In both groups: a first baseline measurements will be performed before initiating therapy and
      a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic
      effect.

      Patients already on treatment with antihypertensive drugs can be included in this study, but
      will undergo a 'wash-out' period of two weeks. After obtaining informed consent, baseline
      physical examination and office blood pressure measurement will be performed. Office blood
      pressure will be measured according to the guidelines of the European Society on Hypertension
      and European Society of Cardiology (ESH-ESC practice guidelines) by an experienced physician.
      Moreover, patients will measure their home blood pressure twice daily: after 5 minutes of
      sitting quietly, three measures spaced by 1-2 minutes will be taken in the morning and in the
      evening. For this purpose, an Omron 705 IT device will be provided to the participants; this
      device has been widely tested in clinical practice and has been validated for use in clinical
      studies (12).

      Throughout the study, the participants will continue his/her regular diet. The goal should be
      to keep the salt intake as stable as possible during the study, since salt intake alters the
      R2* signal. Salt intake will be verified each time before BOLD-MRI measurement by a 24h urine
      collection (dosing volume, creatinine- and sodium-concentration).

      To complete the study we decid to test the acute effect of aliskiren 300mg and Esidrex
      (hydrochlorthiazide) 25mg in 6 healthy volunteers. We will measure the cortical and medullary
      R2* signal before drug intake and 3 hours after drug administration. Each participant will
      take the two drugs in a randomised crossover design. A wash-out period of two week between
      the two administration will be implemented.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Oxygenation Changes After Chronic Treatment With Aliskiren or Hydrochlorothiazide</measure>
    <time_frame>week 0 vs week 8</time_frame>
    <description>Changes in R2* at between week 0 and week 8 as measured by BOLD MRI in the cortex and medulla of the kidney</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aliskiren 150 to 300 mg once a Week for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCTZ 12.5 - 25 mg/d once a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Rasilez</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.</description>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <other_name>Esidrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tolerance to study drugs

          -  Age &gt; 18 years

          -  Arteria hypertension stage 1-2 (blood pressure: 140/90 and 180/110 mm Hg)

          -  Normal renal function

          -  Availability to give informed consent

        Exclusion Criteria:

          -  Intolerance to study drugs

          -  Renal artery stenosis

          -  Hyperkalaemia &gt; 5.0 mmol/l

          -  Contra-indications to the use of PAH, inulin or Lithium

          -  Asthma

          -  Pychiatric illness

          -  No estimated easy vascular venous access for placement of two peripherical venous
             catheters in forearms

          -  Contra-indication to MRI-imaging: Claustrophobia or Pacemaker or other implanted metal
             device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Burnier, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Pruijm M, Hofmann L, Maillard M, Tremblay S, Glatz N, Wuerzner G, Burnier M, Vogt B. Effect of sodium loading/depletion on renal oxygenation in young normotensive and hypertensive men. Hypertension. 2010 May;55(5):1116-22. doi: 10.1161/HYPERTENSIONAHA.109.149682. Epub 2010 Mar 22.</citation>
    <PMID>20308608</PMID>
  </reference>
  <results_reference>
    <citation>Vakilzadeh N, Muller ME, Forni V, Milani B, Hoffman L, Piskunowicz M, Maillard M, Zweiacker C, Pruijm M, Burnier M. Comparative Effect of a Renin Inhibitor and a Thiazide Diuretic on Renal Tissue Oxygenation in Hypertensive Patients. Kidney Blood Press Res. 2015;40(5):542-54. doi: 10.1159/000368530. Epub 2015 Oct 26.</citation>
    <PMID>26501147</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2012</study_first_posted>
  <results_first_submitted>July 28, 2016</results_first_submitted>
  <results_first_submitted_qc>July 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Michel Burnier</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Kidney oxygenation</keyword>
  <keyword>Stage 1 or 2 hypertension</keyword>
  <keyword>BOLD-IRM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>47 patients were screened in a single centre (service of Nephrology, CHUV, Lausanne)</recruitment_details>
      <pre_assignment_details>24 patients were enrolled but 4 were excluded because of the lack of adequate venous access or for other reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>Aliskiren: Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
11 patients were enrolled and completed the study</description>
        </group>
        <group group_id="P2">
          <title>Hydrochlorothiazide</title>
          <description>Hydrochlorothiazide: Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
Finally 9 patients were enrolled and completed the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No possibility to put a catheter</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren</title>
          <description>Patients with essential hypertension stage 1 and 2 .</description>
        </group>
        <group group_id="B2">
          <title>HCTZ</title>
          <description>Patients with essential hypertension stage 1 and 2</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="8.6"/>
                    <measurement group_id="B2" value="49.7" spread="15"/>
                    <measurement group_id="B3" value="52.7" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150" spread="10.7"/>
                    <measurement group_id="B2" value="141" spread="12.9"/>
                    <measurement group_id="B3" value="146" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Renal Oxygenation Changes After Chronic Treatment With Aliskiren or Hydrochlorothiazide</title>
        <description>Changes in R2* at between week 0 and week 8 as measured by BOLD MRI in the cortex and medulla of the kidney</description>
        <time_frame>week 0 vs week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren: Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.</description>
          </group>
          <group group_id="O2">
            <title>Hydrochlorothiazide</title>
            <description>Hydrochlorothiazide: Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Oxygenation Changes After Chronic Treatment With Aliskiren or Hydrochlorothiazide</title>
          <description>Changes in R2* at between week 0 and week 8 as measured by BOLD MRI in the cortex and medulla of the kidney</description>
          <units>1/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cortex week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="1"/>
                    <measurement group_id="O2" value="19.5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cortex week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="1"/>
                    <measurement group_id="O2" value="20.5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren</title>
          <description>Aliskiren: Drug therapy has been started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.</description>
        </group>
        <group group_id="E2">
          <title>Hydrochlorothiazide</title>
          <description>Hydrochlorothiazide: Drug therapy has been started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
No side effect were observed and all patients finished the sudy in this treatment arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of patients who completed the study. Overall underpowered.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof Michel Burnier</name_or_title>
      <organization>Service of Nephrology, Centre Hospitalier Universitaire Vaudois, Lausanne</organization>
      <phone>+41 21 314 11 54</phone>
      <email>michel.burnier@chuv.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

